Related Experiment Video
Updated: May 5, 2026
09:19
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
Published on: December 9, 2014
29.2K
[A therapeutic educational program in Parkinson's disease: ETPARK]
F Ory Magne1, C Arcari1, C Canivet1
1Unité des mouvements anormaux, CHU Purpan, place du Dr-Joseph-Baylac, 31059 Toulouse cedex, France.
Revue Neurologique
|November 26, 2013
Summary
A new therapeutic educational program for Parkinson's disease (PD) improved patient self-esteem. This program enhanced quality-of-life for PD patients without increasing healthcare costs.
Area of Science:
- Neurology
- Health Education
- Patient Support
Context:
- Parkinson's disease (PD) presents unique challenges for patients.
- A needs analysis involving 41 PD patients informed program development.
- Interviews with 395 PD patients guided questionnaire design.
Purpose:
- To develop and evaluate a therapeutic educational program for Parkinson's disease.
- To tailor an educational program to PD specificities and French health authority recommendations.
- To improve patient self-esteem and quality-of-life.
Summary:
- A nurse-led educational program offered individual sessions and group workshops on various PD-related topics.
- The program targeted patients without severe motor or cognitive impairment.
- 231 patients received individual education and 113 attended group workshops between 2008 and 2012.
Impact:
- Patients showed significant improvement in self-esteem after one year.
- A medico-economic study confirmed enhanced quality-of-life for educated patients.
- The program was validated by a regional medical agency and demonstrated cost-effectiveness.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K